このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of ALT001 in Patients With Amyotrophic Lateral Sclerosis

ALT001 is an allogeneic unrelated human umbilical cord mesenchymal stem cell-derived protein complex under investigation for the treatment of amyotrophic lateral sclerosis (ALS). This is a multicenter, randomized, double-blind, placebo-controlled, Phase 2 dose-ranging study in patients with ALS.

Approximately 150 participants will be randomized 1:1:1 to receive ALT001 1.0 μg/kg, ALT001 2.0 μg/kg, or matching placebo by intravenous infusion during the 24-week double-blind (DB) treatment period. During the OLE period, the active treatment groups will continue to receive their original dose under blinded conditions, whereas the placebo group will undergo re-randomization in a 1:1 ratio to receive 1.0 or 2.0 μg/kg ALT001.

The primary objective is to evaluate the dose-response relationship and efficacy of ALT001 at 1.0 and 2.0 μg/kg and to determine the recommended dose for subsequent studies. Secondary objectives include assessment of biomarkers related to efficacy and exploration of changes in cytokines, immune function, proteomics, and immunogenicity (anti-drug antibodies, ADA), as well as evaluation of the safety of ALT001.

調査の概要

研究の種類

介入

入学 (推定)

150

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100070
        • Capital Medical University Affiliated Beijing Tiantan Hospital
        • コンタクト:
          • Yilong Wang, MD, Principal Investigator
          • 電話番号:+86 139 1166 6571
          • メール:yilong528@gmail.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Participants or their guardians must be able to understand the procedures and methods of this study, communicate adequately with the investigator, be willing to strictly comply with the clinical trial protocol to complete the study, and voluntarily sign a written informed consent form, or have informed consent signed by a legally authorized representative.
  2. Age 18 to 75 years (inclusive of both boundaries), of either sex.
  3. Diagnosis of definite or probable ALS according to the revised El Escorial criteria of the World Federation of Neurology for amyotrophic lateral sclerosis, including both familial and sporadic ALS patients.
  4. Forced vital capacity (FVC) ≥ 50% of predicted at the screening visit.
  5. Total ALSFRS-R score ≥ 30 and ≤ 40 prior to enrollment.
  6. If receiving riluzole or edaravone treatment before enrollment, participants must have been on a stable dose for ≥ 30 days prior to Day 1 of this study, and must maintain that dose until the final study visit.

Exclusion Criteria:

  1. Have other known diseases associated with motor neuron dysfunction that may confound or obscure the diagnosis of ALS.
  2. History of alcohol dependence or drug abuse within 6 months prior to screening, judged by the investigator to be unsuitable for participation in this study.
  3. Apparent cognitive impairment (MMSE scale: ≤19 for the illiterate group, ≤22 for the primary school group, and ≤26 for the junior high school and above group [>8 years of education]), or other unstable psychiatric disorders that the investigator considers unsuitable for participation (including suicidal intent, untreated major depression, etc.).
  4. Continuous use of non-invasive ventilation (NIV), diaphragm pacing system, or invasive ventilation (tracheostomy) at screening.
  5. Severe autoimmune diseases, myeloproliferative disorders, leukemia or lymphoma, malignant tumors, fractures, or severe scoliosis at screening, which the investigator considers would affect study evaluation.
  6. Other severe and/or uncontrolled major organ or unstable systemic diseases, including but not limited to uncontrolled diabetes, unstable angina, cerebrovascular accident or transient ischemic attack (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), severe congestive heart failure, uncontrolled hypertension, uncontrolled active infection, severe hepatic, renal or other severe metabolic diseases, or severe gastrointestinal diseases.
  7. Positive hepatitis B surface antigen (HBsAg) with HBV-DNA > upper limit of normal (if HBsAg is negative, HBV-DNA testing is not required); positive hepatitis C virus (HCV) antibody with HCV-RNA > upper limit of normal (if anti-HCV is negative, HCV-RNA testing is not required); positive human immunodeficiency virus (HIV) antibody; or positive Treponema pallidum test.
  8. Pregnant or lactating women, and those planning to conceive during the medication period or within 3 months after stopping the medication.
  9. Participated in another interventional clinical study within 4 weeks prior to this study; received stem cell or exosome therapy within 1 year, or previously received ASO drug treatment or gene therapy.
  10. Judged by the investigator to be unsuitable for participation in this study (e.g., significantly clinically significant abnormalities in physical examination or laboratory tests).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:プラセボ

Matching placebo (ALT001 simulant) containing no active ingredient; identical in appearance, packaging, labeling, and post-reconstitution infusion presentation to ALT001.

実験的:ALT001 1.0 μg/kg

Allogeneic unrelated human umbilical cord mesenchymal stem cell-derived protein complex; 130 μg/vial (lyophilized powder); reconstituted and administered by intravenous infusion at 1.0 μg/kg body weight.

実験的:ALT001 2.0 μg/kg

Allogeneic unrelated human umbilical cord mesenchymal stem cell-derived protein complex; 130 μg/vial (lyophilized powder); reconstituted and administered by intravenous infusion at 2.0 μg/kg body weight.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score
時間枠:Baseline to Week 24 (Week0, Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24 after randomization)

The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is a validated 12-item clinician-reported scale. Total score ranges from 0 to 48, with higher scores indicating better function and lower scores indicating greater functional impairment. A higher (less negative) change from baseline indicates less functional decline.

Baseline to Week 24 (Week0, Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24 after randomization)

二次結果の測定

結果測定
メジャーの説明
時間枠
ALSFRS-R slope from baseline to Week 24 (double-blind period)
時間枠:Baseline to Week 24(Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24 after randomization)

Weekly rate of change in ALSFRS-R total score, calculated as the slope from baseline to Week 24 in the 24-week double-blind period. Higher (less negative) slope indicates slower functional decline.

Baseline to Week 24(Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24 after randomization)
ALSFRS-R slope from baseline to Week 48 (overall study period)
時間枠:Overall study period:Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)

Weekly rate of change in ALSFRS-R total score from baseline to Week 48, including the double-blind and open-label extension periods.

Overall study period:Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)
ALSFRS-R slope from Week 25 to Week 48 (open-label extension period)
時間枠:Week 25 to Week 48 (Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization)

The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is a 12-item clinician-reported scale with a total score ranging from 0 to 48; higher scores indicate better function and lower scores indicate greater functional impairment. The single value reported for this outcome is the slope (rate of change) of the ALSFRS-R total score over time during the 24-week open-label extension (OLE) period, estimated by a mixed model for repeated measures using all post-baseline ALSFRS-R assessments at Weeks 25, 29, 33, 37, 41, 45, and 48. The slope is expressed as change in ALSFRS-R total score per month (points/month); a less negative slope indicates slower functional decline. Only this single slope value is reported for this outcome measure.

Week 25 to Week 48 (Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization)
Assessment of Combined Assessment of Function and Survival (CAFS)
時間枠:Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)

The Combined Assessment of Function and Survival (CAFS) is a single composite outcome that reports ONE value: the CAFS composite rank score. It aggregates two component measurements - (1) survival status and time to death or permanent assisted ventilation, and (2) change from baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score - using a pre-specified ranking rule: each participant is compared pairwise with every other participant, with time to death or permanent assisted ventilation taking precedence (earlier event = worse outcome) and change from baseline in ALSFRS-R total score used for participants who remain alive and free of permanent assisted ventilation (smaller decline = better outcome). The pairwise comparisons are summed to yield a single unitless CAFS composite rank score; higher scores indicate a better combined function-and-survival outcome. The component measurements are aggregated into this one reported value and are not repo

Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)
Assessment of ventilator-free survival (VAFS)
時間枠:Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)

Time from randomization to the first occurrence of non-invasive ventilation, invasive ventilation (tracheostomy), or death due to any cause, whichever occurs first.

Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)
Change from baseline in forced vital capacity (FVC) /slow vital capacity (SVC) percent predictedpercent predicted
時間枠:Baseline to Week 48 (Week 0,Week 13,Week 24, Week25,Week37,Week48)

FVC expressed as percent of predicted normal value, assessed by spirometry. SVC expressed as percent of predicted normal value, assessed by spirometry.

Baseline to Week 48 (Week 0,Week 13,Week 24, Week25,Week37,Week48)
Concentration of cytokines in serum (IFN-γ, IL-10, IL-13, IL-1β, IL-2, IL-4, IL-5, IL-6, GRO-α, TNF-α, IL-2)
時間枠:Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.

Serum concentrations of the following cytokines, measured by central laboratory assay: IFN-γ, IL-10, IL-13, IL-1β, IL-2, IL-4, IL-5, IL-6, GRO-α, TNF-α and IL-2. Concentrations are reported in pg/mL for each cytokine. This outcome measure reports laboratory analyte concentrations, not a score on a scale; therefore an unabbreviated scale title, minimum/maximum score, and score direction do not apply.

Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.
Change from baseline in ALSAQ-40 total score
時間枠:Baseline to Week 48 (Week 0,Week 1, Week 13,Week 24, Week25,Week37,Week48)

The Amyotrophic Lateral Sclerosis Assessment Questionnaire-40 (ALSAQ-40) is a 40-item participant-reported quality-of-life scale; each item is rated on a 5-point scale (0-4). The total score ranges from 0 to 160, with higher scores indicating worse quality of life.

Baseline to Week 48 (Week 0,Week 1, Week 13,Week 24, Week25,Week37,Week48)
Change from baseline in ROADS total score
時間枠:Baseline to Week 48 (Week 0,Week 1, Week 13,Week 24, Week25,Week37,Week48)

The Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) is a 28-item linearly weighted disability scale; each item is scored from 0 to 2, giving a raw total score range of 0-56 that is linearly transformed to a standardized total score ranging from 0 to 146. Higher scores indicate better preserved function (less disability).

Baseline to Week 48 (Week 0,Week 1, Week 13,Week 24, Week25,Week37,Week48)
Change from baseline in modified Ashworth scale score
時間枠:Baseline to Week 48 (Week 0, Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization)

The Modified Ashworth Scale (MAS) is a clinician-rated scale used to assess muscle tone and spasticity during passive movement of the assessed muscle groups. Muscle tone is graded from 0 (no increase in muscle tone) to 4 (affected part rigid), with grade 1+ indicating a slight increase in tone between grades 1 and 2. The minimum score is 0 and the maximum score is 4 for each assessed muscle, with higher scores indicating greater spasticity (a worse outcome). This outcome measure reports the change from baseline in the Modified Ashworth Scale score; a positive change indicates worsening spasticity (a worse outcome).

Baseline to Week 48 (Week 0, Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization)
Change from baseline in grip strength (kg)
時間枠:Baseline to Week 48 (Week 0,Week 13,Week 24, Week25,Week37,Week48 )

Maximum hand grip strength measured by dynamometry, expressed in kilograms.

Baseline to Week 48 (Week 0,Week 13,Week 24, Week25,Week37,Week48 )
Change from baseline in muscle strength (MRC sum score)
時間枠:Baseline to Week 48 (Week 0,Week 13,Week 24, Week25,Week37,Week48 )

Manual muscle testing using the Medical Research Council (MRC) scale summed across specified muscle groups; score ranges from 0 (no contraction) to 5 (normal strength) per muscle, with a higher total sum indicating better strength.

Baseline to Week 48 (Week 0,Week 13,Week 24, Week25,Week37,Week48 )
Change from baseline in ALS Functional Staging System stage
時間枠:Baseline to Week 48(Week 0,Week 13,Week 24, Week25,Week37,Week48 )

ALS Functional Staging System stage, assessed to characterize disease progression.

Baseline to Week 48(Week 0,Week 13,Week 24, Week25,Week37,Week48 )
Concentration of neurofilament light chain (NfL) in plasma
時間枠:Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)

Plasma NfL concentration measured by central laboratory assay.

Week 1, Week 5, Week 9, Week 13, Week 17, Week 21, Week 24, Week 25, Week 29, Week 33, Week 37, Week 41, Week 45, Week 48 after randomization(48 weeks)
Concentration of TAR DNA-binding protein 43 (TDP-43) in plasma
時間枠:Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.

Plasma TDP-43 concentration measured by central laboratory assay.

Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.
Concentration of superoxide dismutase 1 (SOD1) in plasma
時間枠:Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.

Plasma SOD1 concentration measured by central laboratory assay.

Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.
Concentration of immunoglobulins in serum (IgG, IgM, IgA)
時間枠:Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.

Serum concentrations of immunoglobulins measured by central laboratory assay.

Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.
Number and percentage of T-cell subsets in blood (CD3+CD4+, CD3+CD8+, CD28+, CD16+)
時間枠:Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.

Enumeration of T-cell subsets by flow cytometry, including CD3+CD4+/CD3+CD8+ ratio.

Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.
Plasma proteomics profile
時間枠:Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.

Proteomic profiling of plasma samples using a central laboratory platform.

Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.
Incidence of treatment-emergent anti-drug antibodies (ADA)
時間枠:Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.

Number and percentage of participants with treatment-emergent ADA responses to ALT001.

Week 1, Week 13, Week 24, Week 25, Week 37, Week48 after randomization.
Incidence of adverse events (AEs) and serious adverse events (SAEs)
時間枠:From informed consent through 28 days after last dose

Number and percentage of participants with TEAEs and SAEs, graded by NCI CTCAE version 6.0.

From informed consent through 28 days after last dose

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月1日

一次修了 (推定)

2028年1月1日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年8月28日

QC基準を満たした最初の提出物

2026年9月17日

最初の投稿 (実際)

2026年9月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月22日

QC基準を満たした最後の更新が送信されました

2026年9月17日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する